ACADIA Pharmaceuticals PE Ratio 2006-2021 | ACAD

Current and historical p/e ratio for ACADIA Pharmaceuticals (ACAD) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. ACADIA Pharmaceuticals PE ratio as of October 22, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

ACADIA Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-22 18.54 0.00
2021-06-30 24.39 $-1.65 0.00
2021-03-31 25.80 $-1.65 0.00
2020-12-31 53.46 $-1.80 0.00
2020-09-30 41.25 $-1.72 0.00
2020-06-30 48.47 $-1.47 0.00
2020-03-31 42.25 $-1.58 0.00
2019-12-31 42.78 $-1.60 0.00
2019-09-30 35.99 $-1.76 0.00
2019-06-30 26.73 $-1.97 0.00
2019-03-31 26.85 $-2.10 0.00
2018-12-31 16.17 $-1.95 0.00
2018-09-30 20.76 $-2.00 0.00
2018-06-30 15.27 $-2.03 0.00
2018-03-31 22.47 $-2.07 0.00
2017-12-31 30.11 $-2.35 0.00
2017-09-30 37.67 $-2.45 0.00
2017-06-30 27.89 $-2.53 0.00
2017-03-31 34.38 $-2.61 0.00
2016-12-31 28.84 $-2.34 0.00
2016-09-30 31.81 $-2.14 0.00
2016-06-30 32.46 $-1.92 0.00
2016-03-31 27.96 $-1.68 0.00
2015-12-31 35.65 $-1.63 0.00
2015-09-30 33.05 $-1.46 0.00
2015-06-30 41.88 $-1.32 0.00
2015-03-31 32.59 $-1.15 0.00
2014-12-31 31.75 $-0.94 0.00
2014-09-30 24.76 $-0.79 0.00
2014-06-30 22.59 $-0.66 0.00
2014-03-31 24.33 $-0.55 0.00
2013-12-31 24.99 $-0.44 0.00
2013-09-30 27.47 $-0.42 0.00
2013-06-30 18.15 $-0.34 0.00
2013-03-31 7.94 $-0.33 0.00
2012-12-31 4.65 $-0.37 0.00
2012-09-30 2.53 $-0.36 0.00
2012-06-30 1.76 $-0.42 0.00
2012-03-31 2.15 $-0.44 0.00
2011-12-31 1.08 $-0.44 0.00
2011-09-30 1.08 $0.40 2.70
2011-06-30 1.63 $0.39 4.18
2011-03-31 1.62 $0.40 4.05
2010-12-31 1.20 $0.38 3.16
2010-09-30 0.91 $-0.59 0.00
2010-06-30 1.09 $-0.71 0.00
2010-03-31 1.51 $-0.94 0.00
2009-12-31 1.32 $-1.20 0.00
2009-09-30 1.71 $-1.35 0.00
2009-06-30 2.19 $-1.54 0.00
2009-03-31 0.95 $-1.69 0.00
2008-12-31 0.90 $-1.73 0.00
2008-09-30 2.68 $-1.81 0.00
2008-06-30 3.69 $-1.82 0.00
2008-03-31 9.06 $-1.62 0.00
2007-12-31 11.07 $-1.60 0.00
2007-09-30 15.05 $-1.56 0.00
2007-06-30 13.67 $-1.51 0.00
2007-03-31 15.02 $-1.65 0.00
2006-12-31 8.79 $-1.62 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.978B $0.442B
Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76